← Back to Search

Sympathetic Nervous System Analysis for Coronary Artery Dissection

N/A
Recruiting
Led By Marysia Tweet, MD, MS
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For SCAD patients: history of SCAD as confirmed by coronary angiography or cardiac computed tomography angiography
For controls: no cardiac disease history
Must not have
Known or suspected unstable cardiac condition within 4 weeks of the study
Active treatment with anticoagulation or dual antiplatelet therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial compares the stress response and artery health of people who have had a heart artery tear to those who haven't. Researchers will measure how well their body's stress system works and how healthy their arteries are.

Who is the study for?
This study is for individuals with a history of spontaneous coronary artery dissection (SCAD), confirmed by specific heart imaging tests, and healthy volunteers without any cardiac disease. Pregnant women, those with unstable heart conditions recently, or on certain blood thinners can't participate.
What is being tested?
The trial investigates the sympathetic nervous system's activity (our body's fight or flight response) and arterial health in SCAD patients compared to healthy people using non-invasive tests like echocardiograms and carotid ultrasounds.
What are the potential side effects?
Since this study uses non-invasive diagnostic tools rather than medications, side effects are minimal but may include discomfort from tight pressure during tonometry or temporary skin marks from elastography.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My SCAD diagnosis was confirmed through specific heart imaging tests.
Select...
I have never had heart disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had any heart problems in the last month.
Select...
I am currently on blood thinners or taking two types of medication to prevent blood clots.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Arterial stiffness
Arterial thickness
Baroreflex sensitivity
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Spontaneous coronary artery dissection (SCAD) groupExperimental Treatment6 Interventions
Subject with a history of SCAD will undergo a series of diagnostic studies to assess neurovascular function.
Group II: Healthy Control GroupExperimental Treatment6 Interventions
Healthy subjects will undergo a series of diagnostic studies to assess neurovascular function.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Echocardiogram
2016
Completed Phase 2
~1910
Elastography
2011
N/A
~720

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Spontaneous Coronary Artery Dissection (SCAD) often involve managing the sympathetic nervous system and improving arterial health. Medications such as beta-blockers are used to reduce heart rate and blood pressure, thereby decreasing the stress on the arterial walls. This is crucial for SCAD patients as it helps prevent further arterial damage and promotes healing. Additionally, lifestyle changes like smoking cessation and caffeine reduction are recommended to minimize sympathetic nervous system activation, which can exacerbate arterial stress and stiffness. These treatments aim to stabilize the arterial structure and mechanics, reducing the risk of recurrent dissection and improving overall cardiovascular health.
No impairment of sympathetic neurotransmission in stunned myocardium.Reduction of sympathetic inotropic response after ischemia in dogs. Contributor to stunned myocardium.Endoscopic thoracic sympathectomy--its effect in the treatment of refractory angina pectoris.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,333 Previous Clinical Trials
3,060,125 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,928 Previous Clinical Trials
47,765,123 Total Patients Enrolled
Marysia Tweet, MD, MSPrincipal InvestigatorMayo Clinic

Media Library

Spontaneous coronary artery dissection (SCAD) group Clinical Trial Eligibility Overview. Trial Name: NCT05699200 — N/A
Healthy Subjects Research Study Groups: Spontaneous coronary artery dissection (SCAD) group, Healthy Control Group
Healthy Subjects Clinical Trial 2023: Spontaneous coronary artery dissection (SCAD) group Highlights & Side Effects. Trial Name: NCT05699200 — N/A
Spontaneous coronary artery dissection (SCAD) group 2023 Treatment Timeline for Medical Study. Trial Name: NCT05699200 — N/A
~32 spots leftby Aug 2027